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METHODS
METHODS—Quality Of Life/Patient-Reported
Outcomes/Utility Studies
PMD15
RELIABILITY AND VALIDITY OF THE EQ-5D SELF-REPORT
QUESTIONNAIRE IN TAIWAN POPULATION
Chang TJ,Tarn YH
National Defense Medical Center,Taipei,Taiwan
OBJECTIVE: To assess the reliability and validity of a Taiwan
traditional-Chinese version of the EQ-5D instrument in general
population. METHODS: The survey was conducted as a postal
survey in a sample of 12,923 persons in Taiwan in December
2002 using a standardized questionnaire containing the EQ-5D,
the Short Form 12 Health Survey (SF-12) and a demographic
proﬁle. To assess the validity of the EQ-5D, or visual analogue
scale (EQ-VAS), the SF-12 scores and other socio-demographic
variables were examined using Pearson correlation coefﬁcient.
Test-retest reliability was analyzed in a subgroup of 302 respon-
dents measured twice within one month, using kappa and agree-
ment method. RESULTS: The general survey response rate
amounted 1647 of the total 12,923 was 12.7% (Female: 50.4%;
mean age: 42.4 years). The response rate for test-retest reliabil-
ity was 61.3%. Subjects reporting moderate or extreme prob-
lems for EQ-5D dimensions generally had lower SF-12 scores
than those without such problems. Subjects with more chronic
health problems had lower EQ-5D value and EQ-5D VAS score.
The responses on EQ-5D mobility, self-care, usual activity and
pain/discomfort dimension had higher correlation with SF-12
PCS than MCS; however, the responses on EQ-5D anxiety
dimension had higher correlation with the SF-12 MCS than PCS.
Agreement for test-retest reliability of the EQ-5D items ranged
from 76% to 99% (n = 180, interval: 30 days). CONCLU-
SIONS: The traditional Chinese EQ-5D self-classiﬁer appears to
be a valid and reliable measure of the health status in Taiwan
general population. These data provide a basis for further studies
of the Chinese EQ-5D instrument.
PMD16
INVESTIGATING THE CEILING EFFECT IN THE EUROQOL IN
THE U.S GENERAL POPULATION
Bharmal M,Thomas III J
Purdue University, West Lafayette, IN, USA
OBJECTIVES: The presence of a ceiling effect in the EuroQol
(EQ-5D) was investigated. METHODS: Data used were from the
2000 Medical Expenditure Panel Survey (MEPS) that included
the 5-item EQ-5D, the EuroQol visual analogue scale (EQ-VAS),
and the SF-12. Individuals ≥18 years were included in the analy-
sis. Respondents who reported no problems on all of the EQ-5D
dimensions were categorized by SF-12 physical component (PCS)
and SF-12 mental component scores (MCS). Those who scored
at the mean or higher (better health) and those below the mean
(worse health) on PCS or MCS were compared on socio-
demographic characteristics and self-reported medical condi-
tions. Data were analyzed using SAS 8.2 and STATA 8. An alpha
of 0.05 was required for signiﬁcance. RESULTS: A total of
11,248 individuals were included in the study and 5,104
(45.38%) reported no problems on all of the EQ-5D dimensions.
However, such individuals reported diabetes, asthma, high blood
pressure, coronary heart disease, angina, myocardial infarction,
stroke, emphysema, or joint pain. There was no signiﬁcant dif-
ference in the number of chronic medical conditions among
respondents categorized in better health or worse health based
on MCS. However, respondents classiﬁed in better health based
on PCS were less likely to report presence of one or more medical
conditions. They also were more likely to be male, younger, more
educated, and employed. The mean PCS score among individu-
als reporting no problems on EQ-5D was signiﬁcantly lower for
respondents reporting any of the above listed medical conditions
except asthma and emphysema than those not reporting any
medical condition. The mean EQ-VAS score also was signiﬁ-
cantly lower for respondents reporting any of the above medical
conditions except asthma and stroke than those with no medical
conditions. CONCLUSIONS: The EQ-5D appears to have a
ceiling effect. The one-item EQ-VAS was more sensitive than 
the ﬁve-item EQ-5D in detecting respondents with medical 
conditions.
PMD17
USING AN ARTIFICIAL NEURAL NETWORK TO PREDICT
UTILITY SCORES FROM SF-36 DATA
McEwan P1, Kind P2, Dixon S3, Currie CJ4
1Cardiff University, Cardiff, Wales, United Kingdom; 2Outcomes
Research Group,York, United Kingdom; 3Shefﬁeld University, Shefﬁeld,
South Yorkshire, United Kingdom; 4University of Wales College of
Medicine, Cardiff, Wales, United Kingdom
OBJECTIVES: Preliminary studies have generated utility scores
from SF-36 data using linear regression models, providing vari-
able results. Of particular importance is the ability of these
models to overcome ﬂoor effects. The objective of this study was
to determine if an improvement in the accuracy of this model-
ling could be achieved using neural networks. METHODS: Data
on 12,268 subjects were abstracted from the Health Outcomes
Data Repository (HODaR) in Cardiff, UK, and split into train-
ing, validation and test sets. A single layer, feed-forward neural
network was constructed and trained using data from 6268
respondents. A validation set containing data from 3000 respon-
dents was used to ﬁnd the optimal network structure. For com-
parative purposes, a linear regression model was then ﬁtted to
the same data, and both the regression model and neural
network were evaluated using the independent test set data con-
taining 3000 respondents. RESULTS: The following results
related to the minimum and maximum utility scores, lower and
upper quartiles, and median and mean values, respectively.
Actual results from the survey were as follows: -0.48, 1.0, 0.58,
0.88, 0.72, and 0.67, respectively. The “trained” neural network
gave the following values -0.38, 1.0, 0.53, 0.87, 0.72, and 0.68,
respectively; the multiple regression model gave 0.01, 1.0, 0.47,
0.85, 0.69, and 0.67, respectively. Correlations between actual
and predicted utility were 0.82 for the neural network and 0.80
for the regression model. CONCLUSION: In early analysis, the
modest improvement in correlation between actual and predicted
utility scores obtained via the neural network was primarily due
to this class of model being more reliable in mapping lower
utility values (<0.5). The bimodal distribution of EQ5D data (UK
scoring algorithm) complicates standard regression modelling,
favouring the use of these more ﬂexible, data driven neural net-
works. It is hypothesised that these latter methods are more
appropriate.
PMD18
REAL-LIFE PATIENT REPORTED OUTCOMES: DATA MINING
OF CONSUMER SPONTANEOUS REPORTS FOR TWO STATINS
Reynolds MW, Ross S, Fahrbach K, Frame D, James K
Metaworks, Inc, Medford, MA, USA
OBJECTIVE: The objective of this study was to examine how
consumer spontaneous Medwatch reports can be used to
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compare patient-reported outcomes in two statins (Statin A and
Statin B). Medwatch is the Food and Drug Adminstration’s
(FDA) program for reporting serious reactions with drugs and
other medical products. Consumer reports are an increasing
number of those drug safety reports and through March 30,
2003, make up more than 27% of the total Medwatch reports.
METHODS: The QSCANTM software was used to compare the
consumer spontaneous reports of two statins (Statin A and Statin
B), using a signal detection methodology, the proportional
reporting ratio (PRR). The two statins were also individually
compared to the class of statin drugs. RESULTS: Statin A had
32,371 consumer reports of adverse events, and Statin B had a
total of 21,895 consumer reports through the ﬁrst quarter of
2003. Report dates were comparable for the two statins. Com-
pared to Statin B, Statin A had a signiﬁcantly higher proportion
of reports for arterial occlusion, cardiac arrest, increased blood
cholesterol, coronary artery surgery, transient ischemic attack,
and aggravated condition. Statin B had a signiﬁcantly higher
PRR for burning sensation (within nervous system disorders),
diabetes mellitus, and decreased blood pressure. The signiﬁcantly
elevated PRRs for Statin B persisted when compared to all other
statins, whereas Statin A appeared similar to the rest of the statin
class for these particular adverse event reports. CONCLU-
SIONS: Using drug safety signal detection data mining technol-
ogy of consumer-driven spontaneous reports, it is possible to
identify possible areas of drug differention between two drugs
or a single drug and an entire drug class. Consumer Medwatch
reports are spontaneous drug adverse event reports that are vol-
untarily submitted by the consumer and may be an informative
source of real-life patient reported outcomes.
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TRAINING REGULATORY AGENCIES IN PRO EVALUATION:
THE WORKMATS EXPERIENCE
Acquadro C1, Lobo-Luppi L1, Chassany O2
1Mapi Research Institute, Lyon, France; 2Hôpital Saint-Louis, Paris,
France
A survey of European Regulators conducted by the ERIQA
Group evidenced the need of training on HRQL and PRO. To
meet this need ERIQA in collaboration with the Cochrane
HRQL Methods Group proposed an Educational Program on
PRO and HRQL using the Workmats, designed for interactive
learning within a group to facilitate the understanding of key
concepts. In 2002 and 2003, regulators were trained in France
(AFSSAPS, ANAES), in Belgium (INAMI) and in the US (FDA).
Members of the Cochrane Collaboration were also trained
during the Stavanger and Barcelona colloquia. OBJECTIVES: To
assess the relevance and the impact of the Workmats training
from the regulators perspective. METHODS: We provided an
evaluation form at the end of each session. Seven questions were
asked addressing the content, the format and the attitude
towards PROs in the future. RESULTS: Eighty persons were
trained: thirty-two members of the Cochrane Collaboration and
48 regulators. To Question 2: Did you learn some useful infor-
mation? Ninety-seven and one-half percent answered Yes. To
Question 3: Did the workshop come up to your expectations?
Ninety-one and one-third percent answered Yes, 6.2% No and
2.5% did not answer. To Question 6: will this training change
your way of evaluating ﬁles? Ninety-oner and three-ﬁfths percent
of the regulators said Yes, 4.2% said No and 4.2% did not
answer. To Question 7: Would you recommend this workshop
to your colleagues? Sixty-eight and seven-tenths percent said yes,
21.3% said maybe, 3.7% said No and 6.3% did not answer.
CONCLUSION: Workmats proved to be a useful training tool
by providing basic information on PROs and enabling regula-
tors to better understand the ﬁeld. The fact that 91.6% of the
attendees said that this training might change their way of
reviewing ﬁles and 90% might recommend the session to 
colleagues encouraged us to plan sessions in 2004 in other 
European countries and the US.
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PRO INSTRUMENT DEVELOPMENT FOR RARE DISORDERS:
A FOCUS-ED APPROACH
Gold KF1,Tran KT1, Stephens JM1, Kimura A2
1Abt Associates Inc, Bethesda, MD, USA; 2Transkaryotic Therapies Inc,
Cambridge, MA, USA
OBJECTIVES: In the absence of a disease-speciﬁc instrument,
existing generic proﬁles may not be sensitive enough to measure
health-related quality of life in certain disease populations. In
addition, instruments developed for other diseases may have
some face validity but are not ideal. The goal of this research is
to develop an approach for rare disease instrument development
given the challenges of available sample and resources.
METHODS: The functional outcomes for clinical understanding
scale (FOCUS) “focuses” on aspects of rare diseases not captured
in validated instruments. A list of outcome domains is ﬁrst gen-
erated for the rare disorder. A validated instrument (“anchor”)
for a disease with some symptoms common to the rare disease
of interest is then identiﬁed. New items are developed in a similar
scale to the anchor instrument in order to allow joint scoring.
Data are collected to assess the validity and reliability for 1) the
anchor instrument; 2) new items (FOCUS) and 3) the anchor
instrument conjoined with the new items. RESULTS: A FOCUS
instrument was developed for Mucopolysaccharidosis II (MPSII;
Hunters Syndrome (HS)), a rare genetic disorder in children. The
childhood health assessment questionnaire (CHAQ) was selected
as the “anchor” instrument. Items of the HS-FOCUS were gen-
erated for MPSII indicators not covered by the CHAQ. Both the
CHAQ and the HS-FOCUS were tested in MPSII patients and
parents. Five of eight FOCUS domains had a Cronbach’s alpha
of at least 0.84 individually. The reliability of the overall CHAQ
score in MPSII patients was comparable to its original sample
(high 0.80s). The reliability of the CHAQ in conjunction with
the HS-FOCUS was superior to each in isolation. The compound
instrument also showed high face, external and statistical valid-
ity. CONCLUSIONS: This example illustrates the potential
success possible using this FOCUS methodology for meeting the
instrumentation needs for rare diseases.
METHODS
METHODS—Patient Preference Studies
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A DESCRIPTIVE ANALYSIS TO INVESTIGATE THE
DIFFERENCES BETWEEN TRADERS AND NON-TRADERS IN
TIME TRADE OFF
Miller LAN, Mody RR
West Virginia University, Morgantown, WV, USA
OBJECTIVES: The purpose of this study was to examine dif-
ferences between traders and non-traders and characteristics that
are associated with being a non-trader. When eliciting utilities
using the Time Trade-Off (TTO) method, studies have shown
that we can usually anticipate a high level (15–60%) of non-
traders—those people who are not willing to trade any of their
life for improved health. METHODS: A cross-sectional super-
vised self-administered survey was used to assess the perception
of health-related quality of life (HRQOL) and utilities using the
TTO method in the general population of 3 groups: Caucasian
